CN109315769A - It is a kind of for improving the composition and preparation method thereof of human body enteral environment - Google Patents
It is a kind of for improving the composition and preparation method thereof of human body enteral environment Download PDFInfo
- Publication number
- CN109315769A CN109315769A CN201811024291.2A CN201811024291A CN109315769A CN 109315769 A CN109315769 A CN 109315769A CN 201811024291 A CN201811024291 A CN 201811024291A CN 109315769 A CN109315769 A CN 109315769A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- lactobacillus
- human body
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 57
- 229920002752 Konjac Polymers 0.000 claims abstract description 29
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 34
- 235000010448 lactitol Nutrition 0.000 claims description 32
- 239000000832 lactitol Substances 0.000 claims description 32
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 32
- 229960003451 lactitol Drugs 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 31
- 240000002900 Arthrospira platensis Species 0.000 claims description 30
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 30
- 229940082787 spirulina Drugs 0.000 claims description 30
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 27
- 241000186012 Bifidobacterium breve Species 0.000 claims description 27
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 27
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 27
- 229920001503 Glucan Polymers 0.000 claims description 26
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 26
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 26
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 26
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 25
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 24
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 22
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 22
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 21
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 21
- 240000002319 Citrus sinensis Species 0.000 claims description 21
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 21
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 21
- 235000012241 calcium silicate Nutrition 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 235000013399 edible fruits Nutrition 0.000 claims description 21
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 21
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 20
- 229920001661 Chitosan Polymers 0.000 claims description 19
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 17
- 235000010355 mannitol Nutrition 0.000 claims description 17
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 15
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 15
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 15
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 229940039696 lactobacillus Drugs 0.000 claims description 11
- 240000005528 Arctium lappa Species 0.000 claims description 2
- 235000003130 Arctium lappa Nutrition 0.000 claims description 2
- 235000008078 Arctium minus Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 61
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 40
- 230000000968 intestinal effect Effects 0.000 abstract description 21
- 239000004310 lactic acid Substances 0.000 abstract description 20
- 235000014655 lactic acid Nutrition 0.000 abstract description 20
- 230000009286 beneficial effect Effects 0.000 abstract description 16
- 210000000936 intestine Anatomy 0.000 abstract description 14
- 230000012010 growth Effects 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 7
- 230000003993 interaction Effects 0.000 abstract description 7
- 235000013325 dietary fiber Nutrition 0.000 abstract description 6
- 239000003053 toxin Substances 0.000 abstract description 5
- 231100000765 toxin Toxicity 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 230000005176 gastrointestinal motility Effects 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 30
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 29
- 238000009472 formulation Methods 0.000 description 28
- 239000006071 cream Substances 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 12
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 12
- 240000001046 Lactobacillus acidophilus Species 0.000 description 11
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 11
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 10
- 229920001542 oligosaccharide Polymers 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000007613 environmental effect Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 206010010774 Constipation Diseases 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 150000002482 oligosaccharides Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000015141 kefir Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000003124 biologic agent Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007661 gastrointestinal function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241001478240 Coccus Species 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000020167 acidified milk Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000675 anti-caries Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[(2r,3s,4r,5r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical class O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- -1 amine group oligosaccharide Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
This application provides a kind of for improving the composition and preparation method thereof of human body intestinal canal environment, lactic acid bacteria and Bifidobacterium there are many being closed in the composition, by the weight ratio for controlling lactic acid bacteria and Bifidobacterium, so that lactic acid bacteria and bifidobacteria balance in enteron aisle, to effectively inhibit the growth of harmful bacteria and pathogen, and then active balance intestine beneficial bacteria colony, and it is added to a variety of dietary fibers and traditional Chinese medicine ingredients radix bardanae and konjaku in the composition, interaction is played between each ingredient, collectively promote gastrointestinal motility, activate enteron aisle body cell, it can guarantee that the toxin being detained in enteron aisle efficiently excretes in time, and then improve human body intestinal canal flora environment, various composition interaction can guarantee that sufficient amount of viable bacteria smoothly reaches enteron aisle position and for improving human body enteral environment in composition, improve composition Stability, and then extend validity period of composition.
Description
Technical field
The present invention relates to health-care food composition fields, and in particular to a kind of for improving the composition of human body enteral environment
And preparation method thereof.
Background technique
Improve gastrointestinal function to include defaecation, adjust intestinal flora, promote digestion, have mucosal lesion four kinds of auxiliary protection
Function.Balance between intestinal flora is influenced by the interaction etc. of the physiology of host, food, drug and intestinal flora, various
Factor can all destroy the alternate balance of bacterium, cause enteron aisle to turn to harmful bacteria dominance from beneficial bacterium dominance, to cause many
Intestines problem.Therefore, increase the quantity of intestinal beneficial bacterium, reduce harmful bacteria quantity, be the key that guarantee stomach health operating institute
?.
Enteron aisle is the maximum immune organ of human body and the maximum toxin expelling organ of human body.If enteron aisle there is a problem, intestines
Road maintenance is an incremental process, and entire maintenance process follows self cycle period of enteron aisle firmly, had every about two weeks
The improvement of one matter.Then on the basis of improving again, it is again introduced into a new period, then be further improved, so followed
Ring is reciprocal, and helically formula situation rises entire adjustment process, until enteron aisle complete recovery of health.Since last century the mankind
Since studying microorganism, the preventing, treating of disease, in terms of application obtained extensive attention, greatly
Quantity research shows: the digestion and absorption of normal flora and human nutrition have substantial connection in human body intestinal canal, and normal flora is participated in
The absorption and metabolism of cholesterol, steroids, fat, protein, class ester, amino acid and some drugs, if certain factor shadow
It rings and reduces the probiotics in enteron aisle, harmful bacteria mass propagation, enteral microecological balance is broken, and diarrhea etc. will be caused more
Kind clinical symptoms.Clinically it would generally largely use broad-spectrum antibiotic that can also kill simultaneously although harmful bacteria can be killed effectively
Beneficial bacterium causes intestinal bacilli illness, so as to cause disease.
With the development and improvement of living standard of society, the work rhythm of people is getting faster, and health problem is such as just
Secret, tired and hyperlipidemia etc. also annoyings people therewith.People can eliminate a variety of adverse health shapes there is an urgent need to a kind of simultaneously
The nutriment of condition improves quality of life.Enteron aisle is the vitals that human consumption absorbs, and is the foundation of acquired constitution of people.It is strong
Live away from home miscellaneous microorganism in the enteron aisle of health people, these microorganisms are known as enteric bacilli, and enteric bacilli presses certain ratio
Example combines, and interdependence between each strain forms a kind of ecological balance on quality and quantity.Flora imbalance is referring to body a part just
Ratio in normal flora between each strain occurs to change and exceed the state of normal range (NR) by a relatively large margin, and resulting illness is known as
Dysbacteriosis or flora replace disease.Intestinal flora confusion directly results in function of intestinal canal disorder, causes people's constipation, diarrhea, intestines
A series of physiological maladies such as spasm, these physiological maladies will lead to body immunity reduction, hepatic and renal function disorder, body oedema again
Fat physiological problem.
About hundred several bacteriums are inhabited in human intestine, the presence of these normal bacterium phases exists in addition to can inhibit disinfect pathogen
It is bred in enteron aisle outside endangering, and can produce the substance of necessary for human, such as vitamin B and K.Include in human normal bacterium phase
Beneficial bacterium and harmful bacteria, the breeding that the metabolite (such as lactic acid and acetic acid) that beneficial bacterium generates can inhibit harmful bacteria, to health
Maintenance and whole intestines in terms of have comparable help.Harmful bacteria content is not high in general health human body intestinal canal, can not harmful to human,
However variation, stress, aging of the discomfort of body, diet and environment etc. all may be that harmful bacteria increases, and cause enteral bacterium
The disintegration to balance each other, and then cause constipation.Chronic constipation is common one of chronic intestinal disease, intestines bar in constipation Intestinal
The quantity increase of bacterium, field coccus, Fusobacterium, the quantity reduction of Bacillus acidi lactici, Bifidobacterium, bacteroid.
In the prior art, it is done by taking in probiotics to what gastrointestinal bacterial flora environment in human body was improved though occurring
Method, but regulatory function is more single, such as Chinese patent application 2015109649854 provides one kind for improving human body intestines
The biological agent and preparation method thereof of road flora, the biological agent include following components and parts by weight content: lactic acid bacteria 45-68
Part, 30-50 parts of isomerizing lactose powder, 20-50 parts of apple vinegar, 30-50 parts of ferment and 10-30 parts of dietary fiber；When preparation, press
Lactic acid bacteria, apple vinegar and dietary fiber are thoroughly mixed by parts by weight, add isomerizing lactose powder, ferment, continue to stir
It mixes 30-45min and obtains biological agent by sterilizing.Inventive formulation component is constituted simply, can be effectively facilitated in enteron aisle
The growth of beneficial bacterium Bifidobacterium, so that lactic acid bacteria and Bifidobacterium balanced growth in enteron aisle, and inhibit putrefactivebacteria and cause of disease
The growth of bacterium, and then active balance intestine beneficial bacteria colony, preparation process is simple, and quick, target user is extensive, and dosage is few,
Few side effects, stability is good, long shelf-life.But probiotics type is single in this application, regulatory function is also relatively single.
It is for another example disclosed in Chinese patent application 2012104814550 a kind of for improving the pharmaceutical composition of gastrointestinal function
Object and preparation method thereof, the ingredient and its weight proportion which contains are as follows: 20 parts of Lactobacillus rhamnosus, Yue Shi cream bar
30 parts of bacterium, 30 parts of Bifidobacterium, 15 parts of Lactobacillus casei.Pharmaceutical composition of the invention is one kind using integration of drinking and medicinal herbs raw material as group
The health product capsule of part, pharmaceutical composition of the invention is expected to can reach the effect of improving gastrointestinal function, with rhamnose cream bar
Bacterium, Yue Shi lactobacillus, Bifidobacterium, Lactobacillus casei are primary raw material, are process using scientific and reasonable production technology, this
Product function is clear, quality controllable, takes safety.But bacterium used in this application is dead bacterium, people takes rear role
It is unobvious.
For above-mentioned problems faced, therefore it is badly in need of a kind of species multiplicity, collocation is reasonable, long shelf-life, Ke Yibao
It demonstrate,proves sufficient amount of viable bacteria and smoothly reaches enteron aisle position and the composition for improving human body enteral environment.
Summary of the invention
A kind of species multiplicity provided the object of the invention is to overcome above-mentioned defect existing in the prior art,
Collocation is reasonable, long shelf-life, it is ensured that sufficient amount of viable bacteria smoothly reaches enteron aisle position and for improving human body enteral ring
The composition in border and preparation method thereof.
The purpose of the present invention can be achieved through the following technical solutions.
On the one hand, the present invention provides a kind of for improving the composition of human body enteral environment, and the composition includes by weight
Measure the following components of number meter: 0.1-2 parts of lactobacillus reuteri, 0.01-0.05 parts of Lactobacillus rhamnosus, lactobacillus paracasei
0.01-0.1 parts of Lpc-37,1-10 parts of lactitol, 0.1-5 parts of avenabeta glucosan, 0.1-5 parts of radix bardanae and blunt top spirulina
0.1-5 parts.
Further, above-mentioned for improving the composition of human body enteral environment, the composition includes according to parts by weight
Following components: 0.4-1.5 parts of lactobacillus reuteri, 0.02-0.04 parts of Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37
0.04-0.08 parts, 3-8 parts of lactitol, 1-4 parts of avenabeta glucosan, 1-4 parts of radix bardanae and 1-4 parts of blunt top spirulina.
Further, above-mentioned for improving the composition of human body enteral environment, the composition includes according to parts by weight
Following components: 1-1.2 parts of lactobacillus reuteri, 0.03-0.04 parts of Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37
0.05-0.07 parts, 5-7 parts of lactitol, 2-3 parts of avenabeta glucosan, 2-3 parts of radix bardanae and 2-4 parts of blunt top spirulina.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: bite 0.1-3 parts of Lactobacillus lactis, 0.1-3 parts of animal bifidobacteria, 0.1-2.5 parts of bifidobacterium lactis, Lactobacillus salivarius 0.1-2
Part, 0.1-5 parts of lactobacillus plantarum, 0.1-3 parts of lactobacillus fermenti and 0.3-6 parts of bifidobacterium breve.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: bite 0.5-2.5 parts of Lactobacillus lactis, 0.5-2.5 parts of animal bifidobacteria, 0.5-2 parts of bifidobacterium lactis, Lactobacillus salivarius 0.5-
1.5 parts, 1-4 parts of lactobacillus plantarum, 1-2.5 parts of lactobacillus fermenti and 1-5 parts of bifidobacterium breve.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: bite 1-2 parts of Lactobacillus lactis, 1-2 parts of animal bifidobacteria, 1-2 parts of bifidobacterium lactis, 1-1.5 parts of Lactobacillus salivarius, plant cream
2-3 parts of bacillus, 1-2 parts of lactobacillus fermenti and 2-4 parts of bifidobacterium breve.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 1-5 parts of oligofructose, 0.1-1 parts of galactooligosaccharide, 0.5-6 parts of Oligomeric manna sugar, 0.1-5 parts of chitosan, different malt are oligomeric
Sugared 0.1-5 parts and stachyose 0.1-6 parts.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 2-4 parts of oligofructose, 0.5-0.8 parts of galactooligosaccharide, 1-5 parts of Oligomeric manna sugar, 1-4 parts of chitosan, isomalto-oligosaccharide
1-4 parts and stachyose 1-5 parts.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 3-4 parts of oligofructose, 0.6-0.7 parts of galactooligosaccharide, 2-4 parts of Oligomeric manna sugar, 3-4 parts of chitosan, isomalto-oligosaccharide
2-3 parts and stachyose 2-4 parts of
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 0.5-10 parts and konjaku 0.1-5 parts of DHA algal oil.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 1-8 parts and konjaku 1-4 parts of DHA algal oil.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 4-5 parts and konjaku 2-3 parts of DHA algal oil.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 0.5-5 parts of sweet orange fruit powder, 0.05-0.15 parts of citric acid powder and 0.1-0.3 parts of calcium silicates.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 1-4 parts of sweet orange fruit powder, 0.08-0.12 parts of citric acid powder and 0.15-0.25 parts of calcium silicates.
Further, above-mentioned for improve the composition of human body enteral environment to further include according to parts by weight with the following group
Point: 2-3 parts of sweet orange fruit powder, 0.1-0.12 parts of citric acid powder and 0.1-0.2 parts of calcium silicates.
Wherein, described to bite Lactobacillus lactis, Roy's formula lactobacillus, lactobacillus plantarum, Lactobacillus salivarius and lactobacillus fermenti
Weight ratio be 1-1.5: 1: 1-2.5: 1: 1-1.5；
The weight ratio of the Lactobacillus rhamnosus and lactobacillus paracasei Lpc-37 is 1: 1-8.
Preferably, described to bite Lactobacillus lactis, Roy's formula lactobacillus, lactobacillus plantarum, Lactobacillus salivarius and acidified milk bar
The weight ratio of bacterium is 1-1.2: 1: 1-2.0: 1: 1-1.2；
The weight ratio of the Lactobacillus rhamnosus and lactobacillus paracasei Lpc-37 is 1: 2-7.
More preferably, described to bite Lactobacillus lactis, Roy's formula lactobacillus, lactobacillus plantarum, Lactobacillus salivarius and acidified milk
The weight ratio of bacillus is 1-1.1: 1: 1-1.5: 1: 1-1.1；
The weight ratio of the Lactobacillus rhamnosus and lactobacillus paracasei Lpc-37 is 1: 4-5.
The weight ratio of the animal bifidobacteria, bifidobacterium lactis and bifidobacterium breve is 1-1.2: 1: 1-2.4；It is preferred that
Ground, the weight ratio of the animal bifidobacteria, bifidobacterium lactis and bifidobacterium breve are 1-1.1: 1: 1-2.0；More preferably,
The weight ratio of the animal bifidobacteria, bifidobacterium lactis and bifidobacterium breve is 1-1.1: 1: 1-1.5.
The weight ratio of the chitosan, avenabeta glucosan and isomalto-oligosaccharide is 1: 1: 1；
The weight ratio of the oligofructose and lactitol is 1: 1-8.
Preferably, the weight ratio of the chitosan, avenabeta glucosan and isomalto-oligosaccharide is 1: 1: 1；
The weight ratio of the oligofructose and lactitol is 1: 2-7.
More preferably, the weight ratio of the chitosan, avenabeta glucosan and isomalto-oligosaccharide is 1: 1: 1；
The weight ratio of the oligofructose and lactitol is 1: 4-6.
The weight ratio of the blunt top spirulina and DHA algal oil is 1: 2-5.
The weight ratio of the radix bardanae and konjaku is 1: 1.
The viable count of the lactic acid bacteria is 1,500,000,000/g.
The viable count of the Bifidobacterium is 2,000,000,000/g.
Oligofructose: being a kind of natural active matter.Sugariness is 0.3-0.6 times of sucrose.Both the pure of sucrose had been maintained
Sweetening characteristics, but it is salubriouser than sucrose sweet taste.It is to have to adjust intestinal flora, is proliferated Bifidobacterium, promotes the absorption of calcium, adjust blood
Rouge, immunological regulation, the novel sweetener of the healthcare functions such as anti-caries tooth are known as most potential a new generation after the antibiotic epoch
Additive --- growth-promoting substance.
Galactooligosaccharide: galactooligosaccharide (Galactooligosaccharides, GOS) is a kind of with natural attribute
Functional oligose, molecular structure be usually on galactolipin or glucose molecule connect 1~7 galactosyl, i.e.,
Gal- (Gal) n-Glc/Gal (n 0-6).Galactooligosaccharide is that Bifidobacterium in human body intestinal canal, Lactobacillus acidophilus etc. are beneficial
The fabulous nutrient source of bacterium and effective proliferation factor, can improve the digestion and absorption function of human body intestinal canal.
Isomalto-oligosaccharide: i.e. 3344 isomalto-oligosaccharides (Isomalto-oligosaeeharides) also known as divide
Branch oligosaccharide (Branchingoligosaccharide), isomaltulose or branchiness malto-oligosaccharide, it is a kind of emerging
Functional oligose has water-soluble dietary fiber function, calorific value since it can promote the intracorporal Bifidobacterium of people to be significantly proliferated
The characteristics such as low, anti-caries, so being a kind of widely used functional oligose.
Stachyose: being a kind of naturally occurring tetrose, is that a kind of can remarkably promote the beneficial bacteriums such as Bifidobacterium and be proliferated
Functional oligose has extremely apparent proliferation function to profitable strains such as Bifidobacterium, Bacillus acidi lacticis in human gastrointestinal tract,
Environment in human body alimentary canal can be improved rapidly, adjust Tiny ecosystem colony balance.
Oligomeric manna sugar: it is that main chain is formed by β-Isosorbide-5-Nitrae glucosides key connection by D-MANNOSE, is connected on main chain or branch
Glucose forms, oligosaccharides of the degree of polymerization between 2~10.It is a kind of novel prebiotics, can largely be activated and proliferation bifid
Bacillus and lactic acid bacteria adjust microecological balance.
Lactitol: also known as newborn pears alcohol, is a kind of health sweetener, and lactitol can be used as quality improver for domestic animal
The hobby that animal is improved in feed also can promote Bifidobacterium in animal body and be proliferated, and the chemical nature of lactitol is 4-O-
β-D- galactopyranose-D-glucitol, molecular formula C12H24O11, molecular weight 344.32.The lactitol of crystallization mainly has two
Kind form: the pure and mild Lactose hydrate alcohol of two Lactose hydrates, separately having a kind of lactitol commodity is that the lactitol containing lactitol 54% is molten
Liquid.
Chitosan oligosaccharide: being called Chitosan poly oligosaccharide, chitosan oligomer, is that chitosan (is also had use through special biological enzyme technology
The report of chemical degradation, microwave degradation technology) a kind of obtained degree of polymerization of degrading oligosaccharide product between 2~20, molecular weight≤
3200Da is water-soluble low molecular weight product preferable, function is big, bioactivity is high.It has chitosan unexistent
Higher solubility is dissolved in water entirely, is easy many unique functions such as to be absorbed and utilized by organism, it acts as the 14 of chitosan
Times.Chitosan oligosaccharide is unique positively charged cationic basic amine group oligosaccharide in nature, is animal fiber element.It is widely applied
In activation factor of the field of food as beneficial bacteria of intestinal tract (such as Bifidobacterium Bifidum), promote the absorption of calcium and minerals.
Avenabeta glucosan: avenabeta glucosan is a kind of water-soluble dietary fiber, the stickiness having by it hinder starch,
The digestion and absorption of the substances such as protein, so can have significant drop blood with some extremely advantageous physiological functions to human body
Rouge, hypoglycemic and raising immunocompetence, maintain intestine microenvironment.
Radix bardanae: it is bitter in taste, it trembles with fear, is nontoxic.Channel tropism is distributed in lung channel；The heart channel of Hang-Shaoyin.Cure mainly wind-dispelling heat, detumescence poison.Control wind toxin edema of the face, head
Dizzy, throat heat is swollen, dentalgia, and cough is quenched one's thirst, ulcer sore scabies.
Konjaku: it is cold in nature, pungent, it is toxic；Can activating microcirculation and removing stasis medicinal, removing toxicity for detumescence, wide intestines defaecation, resolving phlegm and softening hard masses；Cure mainly blood pressure lowering, drop
The diseases such as blood glucose, scrofula subcutaneous nodule, the damage stasis of blood swollen, constipation abdominal pain, abscess of throat, swelling and aching of gum.It replenishes the calcium, put down in addition, konjaku also has
The effects of weighing apparatus salinity, clean stomach, whole intestines, toxin expelling.
Blunt top spirulina: main function be improve immunity of organisms, promote enterogastric peristalsis, supplement body conventional element and
Microelement.
DHA algal oil: docosahexaenoic acid is commonly called as docosapentaenoic acid, is a kind of pair of very important polyunsaturated fat of human body
Acid belongs to the important member in Omega-3 unsaturated fatty acid family.
On the other hand, it is above-mentioned for improving the preparation method of human body enteral environmental compositions that the present invention also provides one kind,
Specifically include step are as follows:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Resulting composition of the present invention can also be processed into tablet, granule, pill, powder, mouth containing agent or pulvis, can also make
It is the addition of bottom side in other products.
Compared with prior art, the invention has the following advantages that
(1) contain various lactobacillus and Bifidobacterium in the composition disclosed in this invention for improving human body enteral environment,
By controlling the weight ratio of lactic acid bacteria and Bifidobacterium, so that lactic acid bacteria and bifidobacteria balance in enteron aisle, thus effectively
The growth for inhibiting harmful bacteria and pathogen, and then active balance intestine beneficial bacteria colony.
(2) composition disclosed by the invention is added to a variety of dietary fibers, i.e., on the basis of lactic acid bacteria and Bifidobacterium
Oligofructose, galactooligosaccharide etc. play interaction between each ingredient, collectively promote gastrointestinal motility, and activation enteron aisle body is thin
Born of the same parents, it is ensured that the toxin being detained in enteron aisle efficiently excretes in time, and then improves human body intestinal canal flora environment.
(3) present invention is also added into certain content radix bardanae and konjaku in the composition, in both ingredients and composition
Other compositions interaction can guarantee that sufficient amount of viable bacteria smoothly reaches enteron aisle position and for improving human body enteral ring
Border, improves the stability of composition, and then extends the validity period of composition.
(4) blunt top spirulina and DHA algal oil, blunt top spirulina and DHA algal oil are added in composition disclosed by the invention
The effect of composition is further improved with other compositions interaction in composition, keeps the composition quick, is suitable for more
Kind of crowd, dosage is few and few side effects, will not generate dependence.
Specific embodiment
The present invention is described in detail combined with specific embodiments below.
Embodiment 1 is a kind of for improving the composition of human body enteral environment
It comprises the following components in parts by weight:
Bite 0.1 part of Lactobacillus lactis, 0.3 part of animal bifidobacteria, 0.3 part of bifidobacterium lactis, 0.1 part of lactobacillus reuteri,
0.2 part of lactobacillus plantarum, 0.1 part of Lactobacillus salivarius, 0.02 part of Lactobacillus rhamnosus, 0.02 part of lactobacillus paracasei Lpc-37,
0.1 part of lactobacillus fermenti, 0.4 part of bifidobacterium breve, 1 part of oligofructose, 5 parts of lactitol, 0.3 part of galactooligosaccharide, different malt
It is 0.2 part of oligosaccharide, 0.1 part of radix bardanae, 0.1 part of konjaku, 0.1 part of blunt top spirulina, 0.5 part of DHA algal oil, 0.1 part of stachyose, low
0.5 part of poly- mannose, 0.2 part of chitosan, 0.2 part of avenabeta glucosan, 2 parts of sweet orange fruit powder, 0.1 part of citric acid powder and calcium silicates
0.1 part.
Wherein, the viable count of lactic acid bacteria is 1,500,000,000/g；The viable count of Bifidobacterium is 2,000,000,000/g.
The present embodiment be used for improve human body enteral environmental compositions preparation method specifically includes the following steps:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Embodiment 2 is a kind of for improving the composition of human body enteral environment
It comprises the following components in parts by weight:
Bite 0.3 part of Lactobacillus lactis, 0.3 part of animal bifidobacteria, 0.25 part of bifidobacterium lactis, 0.2 part of lactobacillus reuteri,
0.5 part of lactobacillus plantarum, 0.2 part of Lactobacillus salivarius, 0.02 part of Lactobacillus rhamnosus, 0.04 part of lactobacillus paracasei Lpc-37,
0.2 part of lactobacillus fermenti, 0.4 part of bifidobacterium breve, 2 parts of oligofructose, 5 parts of lactitol, 0.4 part of galactooligosaccharide, different malt
It is 0.3 part of oligosaccharide, 0.2 part of radix bardanae, 0.2 part of konjaku, 0.2 part of blunt top spirulina, 1 part of DHA algal oil, 0.3 part of stachyose, oligomeric
1 part of mannose, 0.3 part of chitosan, 0.3 part of avenabeta glucosan, 3 parts of sweet orange fruit powder, 0.08 part of citric acid powder and calcium silicates 0.1
Part.
Wherein, the viable count of lactic acid bacteria is 1,500,000,000/g；The viable count of Bifidobacterium is 2,000,000,000/g.
The present embodiment be used for improve human body enteral environmental compositions preparation method specifically includes the following steps:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Embodiment 3 is a kind of for improving the composition of human body enteral environment
It comprises the following components in parts by weight:
Bite 0.5 part of Lactobacillus lactis, 0.5 part of animal bifidobacteria, 0.5 part of bifidobacterium lactis, 0.5 part of lactobacillus reuteri,
1 part of lactobacillus plantarum, 0.5 part of Lactobacillus salivarius, 0.03 part of Lactobacillus rhamnosus, 0.04 part of lactobacillus paracasei Lpc-37, hair
0.5 part of kefir milk bacillus, 0.6 part of bifidobacterium breve, 3 parts of oligofructose, 7 parts of lactitol, 0.6 part of galactooligosaccharide, different malt are low
It is 0.5 part of glycan, 0.5 part of radix bardanae, 0.5 part of konjaku, 0.5 part of blunt top spirulina, 2 parts of DHA algal oil, 0.6 part of stachyose, oligomeric sweet
2 parts of dew sugar, 0.5 part of chitosan, 0.5 part of avenabeta glucosan, 2 parts of sweet orange fruit powder, 0.06 part of citric acid powder and calcium silicates 0.2
Part.
Wherein, the viable count of lactic acid bacteria is 1,500,000,000/g；The viable count of Bifidobacterium is 2,000,000,000/g.
The present embodiment be used for improve human body enteral environmental compositions preparation method specifically includes the following steps:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Embodiment 4 is a kind of for improving the composition of human body enteral environment
It comprises the following components in parts by weight:
Bite 1 part of Lactobacillus lactis, 1 part of animal bifidobacteria, 1 part of bifidobacterium lactis, 1 part of lactobacillus reuteri, plant cream bar
2 parts of bacterium, 1 part of Lactobacillus salivarius, 0.04 part of Lactobacillus rhamnosus, 0.06 part of lactobacillus paracasei Lpc-37, lactobacillus fermenti 1
Part, 1 part of bifidobacterium breve, 4 parts of oligofructose, 8 parts of lactitol, 1 part of galactooligosaccharide, 1 part of isomalto-oligosaccharide, radix bardanae 1
Part, 1 part of konjaku, 1 part of blunt top spirulina, 3 parts of DHA algal oil, 1 part of stachyose, 4 parts of Oligomeric manna sugar, 1 part of chitosan, oat β-
1 part of glucan, 4 parts of sweet orange fruit powder, 0.1 part of citric acid powder and 0.2 part of calcium silicates.
Wherein, the viable count of lactic acid bacteria is 1,500,000,000/g；The viable count of Bifidobacterium is 2,000,000,000/g.
The present embodiment be used for improve human body enteral environmental compositions preparation method specifically includes the following steps:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Embodiment 5 is a kind of for improving the composition of human body enteral environment
It comprises the following components in parts by weight:
0.3 part of lactobacillus acidophilus, 0.6 part of animal bifidobacteria, 0.5 part of bifidobacterium lactis, 0.2 part of lactobacillus reuteri,
0.5 part of lactobacillus plantarum, 0.2 part of Lactobacillus salivarius, 0.04 part of Lactobacillus rhamnosus, 0.05 part of lactobacillus paracasei Lpc-37,
0.3 part of lactobacillus fermenti, 0.6 part of bifidobacterium breve, 3 parts of oligofructose, 6 parts of lactitol, 0.6 part of galactooligosaccharide, different malt
It is 0.5 part of oligosaccharide, 0.5 part of radix bardanae, 0.5 part of konjaku, 0.5 part of blunt top spirulina, 1 part of DHA algal oil, 0.6 part of stachyose, oligomeric
1 part of mannose, 0.5 part of chitosan oligosaccharide, 0.5 part of avenabeta glucosan, 3 parts of sweet orange fruit powder, 0.12 part of citric acid powder and calcium silicates 0.1
Part.
Wherein, the viable count of lactic acid bacteria is 1,500,000,000/g；The viable count of Bifidobacterium is 2,000,000,000/g.
The present embodiment be used for improve human body enteral environmental compositions preparation method specifically includes the following steps:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Embodiment 6 is a kind of for improving the composition of human body enteral environment
It comprises the following components in parts by weight:
Bite 3 parts of Lactobacillus lactis, 3 parts of animal bifidobacteria, 2.5 parts of bifidobacterium lactis, 2 parts of lactobacillus reuteri, plant cream
5 parts of bacillus, 2 parts of Lactobacillus salivarius, 0.05 part of Lactobacillus rhamnosus, 0.1 part of lactobacillus paracasei Lpc-37, lactobacillus fermenti 3
Part, 6 parts of bifidobacterium breve, 5 parts of oligofructose, 10 parts of lactitol, 6 parts of galactooligosaccharide, 5 parts of isomalto-oligosaccharide, radix bardanae 5
Part, 5 parts of konjaku, 5 parts of blunt top spirulina, 10 parts of DHA algal oil, 6 parts of stachyose, 10 parts of Oligomeric manna sugar, 5 parts of chitosan, oat
5 parts of beta glucan, 5 parts of sweet orange fruit powder, 0.15 part of citric acid powder and 0.2 part of calcium silicates.
Wherein, the viable count of lactic acid bacteria is 1,500,000,000/g；The viable count of Bifidobacterium is 2,000,000,000/g.
The present embodiment be used for improve human body enteral environmental compositions preparation method specifically includes the following steps:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Embodiment 7 is a kind of for improving the composition of human body enteral environment
It comprises the following components in parts by weight:
Bite 2.5 parts of Lactobacillus lactis, 2.5 parts of animal bifidobacteria, 2.0 parts of bifidobacterium lactis, 1.8 parts of lactobacillus reuteri,
4.5 parts of lactobacillus plantarum, 1.8 parts of Lactobacillus salivarius, 0.04 part of Lactobacillus rhamnosus, 0.08 part of lactobacillus paracasei Lpc-37,
2.6 parts of lactobacillus fermenti, 5.0 parts of bifidobacterium breve, 4 parts of oligofructose, 10 parts of lactitol, 5.5 parts of galactooligosaccharide, different malt
It is 4.5 parts of oligosaccharide, 4.5 parts of radix bardanae, 4.5 parts of konjaku, 4.5 parts of blunt top spirulina, 9 parts of DHA algal oil, 5.5 parts of stachyose, oligomeric
9 parts of mannose, 4.5 parts of chitosan, 4.5 parts of avenabeta glucosan, 4 parts of sweet orange fruit powder, 0.12 part of citric acid powder and calcium silicates 0.2
Part.
Wherein, the viable count of lactic acid bacteria is 1,500,000,000/g；The viable count of Bifidobacterium is 2,000,000,000/g.
The present embodiment be used for improve human body enteral environmental compositions preparation method specifically includes the following steps:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Embodiment 8 is a kind of for improving the composition of human body enteral environment
It comprises the following components in parts by weight:
Bite 1.5 parts of Lactobacillus lactis, 2.4 parts of animal bifidobacteria, 2.0 parts of bifidobacterium lactis, 1.5 parts of lactobacillus reuteri,
3 parts of lactobacillus plantarum, 1.5 parts of Lactobacillus salivarius, 0.02 part of Lactobacillus rhamnosus, 0.05 part of lactobacillus paracasei Lpc-37, hair
2 parts of kefir milk bacillus, 4 parts of bifidobacterium breve, 4 parts of oligofructose, 6 parts of lactitol, 4 parts of galactooligosaccharide, isomalto-oligosaccharide 3
Part, 3 parts of radix bardanae, 3 parts of konjaku, 3 parts of blunt top spirulina, 5 parts of DHA algal oil, 4 parts of stachyose, 6 parts of Oligomeric manna sugar, chitosan 3
Part, 3 parts of avenabeta glucosan, 3 parts of sweet orange fruit powder, 0.15 part of citric acid powder and 0.3 part of calcium silicates.
Wherein, the viable count of lactic acid bacteria is 1,500,000,000/g；The viable count of Bifidobacterium is 2,000,000,000/g.
The present embodiment be used for improve human body enteral environmental compositions preparation method specifically includes the following steps:
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, lactobacillus reuteri, plant cream are weighed by formulation dosage
Bacillus, Lactobacillus salivarius, Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37, lactobacillus fermenti and bifidobacterium breve, mixing are equal
Be added after even the oligofructose of formulation dosage, lactitol, galactooligosaccharide, isomalto-oligosaccharide, stachyose, Oligomeric manna sugar,
Chitosan oligosaccharide, avenabeta glucosan, sweet orange fruit powder, citric acid powder and calcium silicates are stirred, and are eventually adding the fructus arctii of formulation dosage
Root, konjaku, blunt top spirulina and DHA algal oil continue stir 20-50min after, sterilizing, it is canned to get arrive composition.
Comparative example 1
Difference with embodiment 3 is: biting Lactobacillus lactis, Roy's formula lactobacillus, lactobacillus plantarum, Lactobacillus salivarius and hair
The weight ratio of kefir milk bacillus is 0.5: 1: 0.5: 1: 0.5；Other operations are same as Example 3 with step.
Comparative example 2
Difference with embodiment 3 is: biting Lactobacillus lactis, Roy's formula lactobacillus, lactobacillus plantarum, Lactobacillus salivarius and hair
The weight ratio of kefir milk bacillus is 2: 1: 5: 1: 3；Other operations are same as Example 3 with step.
Comparative example 3
Difference with embodiment 5 is: the weight ratio of animal bifidobacteria, bifidobacterium lactis and bifidobacterium breve is 0.5:
1:0.5；Other operations are same as Example 5 with step.
Comparative example 4
Difference with embodiment 5 is: the weight ratio of animal bifidobacteria, bifidobacterium lactis and bifidobacterium breve is 4: 1:
5；Other operations are same as Example 5 with step.
Embodiment 5
Difference with embodiment 6 is: the weight ratio of blunt top spirulina and DHA algal oil is 1: 0.5；Other operations and step
It is same as Example 6.
Embodiment 6
Difference with embodiment 6 is: the weight ratio of blunt top spirulina and DHA algal oil is 1: 8；Other operation with step with
Embodiment 6 is identical.
Comparative example 7
Difference with embodiment 6 is: burdock grass and konjaku are free of in composition；Other operations and step and embodiment 6
It is identical.
Comparative example 8
Difference with embodiment 6 is: blunt top spirulina and DHA algal oil are free of in composition；Other operation with step with
Embodiment 6 is identical.
Comparative example 9
A kind of pharmaceutical composition for improving function of intestinal canal disclosed in Chinese patent application 2012104814550 and its
Pharmaceutical composition disclosed in preparation method.
The efficient detection of test example 1
900 people with diarrhea or constipation are chosen, the age is 30-60 one full year of life, it is randomly divided into 18 groups, every group of 50 people,
Respectively 1-18 group, wherein the 1-8 group combination for being used to improve human body enteral environment that daily embodiment 1-8 is provided respectively
Object, 9-18 group take the composition of comparative example 1-10 offer respectively, and dose is that once a day, each 10g takes 3 months
Afterwards, curative effect statistics is carried out, the results are shown in Table 1.
Table 1
It can be seen that the composition provided by the invention for improving human body enteral environment from the data comparison of table 1, by various
Different lactobacillus and Bifidobacterium interaction, and joined the prebiotics and traditional Chinese medicine ingredients fructus arctii of certain content in formula
Root and konjaku and blunt top spirulina and DHA algal oil can be obviously improved intestinal environment, have for diarrhea and constipation symptom bright
The effect of aobvious to improve, and the mass ratio for changing individual components in the application can influence composition to a certain extent, but still
The effect of better than composition is disclosed in the prior art, i.e. explanation, only use the composition of component disclosed by the invention and proportion,
Intestinal microecology could be preferably adjusted, diarrhea and constipation symptom can be effectively prevented and treat.
The monitoring of 2 beneficial effect of test example
According to Dalian Medical Univ's Zhou Jingxin master thesis, " several prebiotic preparations make intestinal flora to experimental method
With the research of effect " method of experiment in vitro and dosage are tested in the paper of code Y1044452, and ferment 12 hours hindguts
Road Microflora measurement, as a result such as the control group phase of following table each embodiment group intestinal flora and the glucose for being incorporated as same dose
Compare, observe the variation of harmful bacteria enterobacteria, enterococcus and beneficial bacteria Bifidobacterium, Bacillus acidi lactici, specific data are shown in
Table 2.
Table 2
Ferment 12 hours rear intestinal Microfloras (lgCFU/g, it is wet just, average ± standard deviation, n=5)
By the detection data of upper table 2, it is apparent that taking the composition disclosed in the present application for improving enteral environment
Excrement, after fermentation 12 hours, the measurement of intestinal microflora, Bifidobacterium, lactobacillus, the enterobacteria, intestines of each embodiment group
Coccus increased, but lactobacillus and Bifidobacterium obviously increase, and illustrate that composition disclosed herein passes through control
The content of probiotics and prebiotics and other each ingredients enables the composition of preparation preferably to promote to have in enteron aisle with proportion
The growth of beneficial bacteria inhibits the growth of harmful bacteria, is more conducive to improve enteral environment.And by changing various components in comparative example
Mass ratio makes harmful bacteria increasing degree in enteron aisle be apparently higher than composition disclosed in embodiment, but is still lower than the prior art
Disclosed in composition；Beneficial bacterium increasing degree is still higher than in the prior art lower than composition disclosed in embodiment
Disclosed composition, i.e., only can be better using the composition that the component of content disclosed by the invention and proportion is prepared into
Improve enteral environment.
The above description is only an embodiment of the present invention, is not intended to limit the scope of the invention, all to utilize this hair
Equivalent structure or equivalent flow shift made by bright description is applied directly or indirectly in other relevant technology necks
Domain is included within the scope of the present invention.
Claims (10)
1. a kind of for improving the composition of human body enteral environment, it is characterised in that: the composition includes according to parts by weight
Following components: 0.1-2 parts of lactobacillus reuteri, 0.01-0.05 parts of Lactobacillus rhamnosus, lactobacillus paracasei Lpc-37
0.01-0.1 parts, 1-10 parts of lactitol, 0.1-5 parts of avenabeta glucosan, 0.1-5 parts of radix bardanae and 0.1-5 parts of blunt top spirulina.
2. according to claim 1 for improving the composition of human body enteral environment, it is characterised in that: the composition is also
Including following components according to parts by weight: biting 0.1-3 parts of Lactobacillus lactis, 0.1-3 parts of animal bifidobacteria, bifidobacterium lactis
0.1-2.5 parts, 0.1-2 parts of Lactobacillus salivarius, 0.1-5 parts of lactobacillus plantarum, 0.1-3 parts of lactobacillus fermenti and bifidobacterium breve
0.3-6 parts.
3. according to claim 1 for improving the composition of human body enteral environment, it is characterised in that: the composition is also
Including following components according to parts by weight: 1-5 parts of oligofructose, 0.1-1 parts of galactooligosaccharide, 0.5-6 parts of Oligomeric manna sugar,
0.1-5 parts of chitosan, 0.1-5 parts of isomalto-oligosaccharide and 0.1-6 parts of stachyose.
4. according to claim 1 for improving the composition of human body enteral environment, it is characterised in that: the composition is also
Including following components according to parts by weight: 0.5-10 parts and konjaku 0.1-5 parts of DHA algal oil.
5. according to claim 1 for improving the composition of human body enteral environment, it is characterised in that: the composition is also
Including following components according to parts by weight: 0.5-5 parts of sweet orange fruit powder, 0.05-0.15 parts of citric acid powder and calcium silicates 0.1-0.3
Part.
6. according to claim 1 or 2 for improving the composition of human body enteral environment, it is characterised in that: described bites
Lactobacillus lactis, Roy's formula lactobacillus, lactobacillus plantarum, Lactobacillus salivarius and lactobacillus fermenti weight ratio be 1-1.5: 1: 1-
2.5:1:1-1.5；
The weight ratio of the Lactobacillus rhamnosus and lactobacillus paracasei Lpc-37 is 1: 1-8.
7. according to claim 2 for improving the composition of human body enteral environment, it is characterised in that: the animal is double
The weight ratio of discrimination bacillus, bifidobacterium lactis and bifidobacterium breve is 1-1.2: 1: 1-2.4.
8. according to claim 1 or 3 for improving the composition of human body enteral environment, it is characterised in that: the shell
The weight ratio of glycan, avenabeta glucosan and isomalto-oligosaccharide is 1: 1: 1；
The weight ratio of the oligofructose and lactitol is 1: 1-2.
9. according to claim 1 or 4 for improving the composition of human body enteral environment, it is characterised in that: the ox
The weight ratio of burdock root and konjaku is 1: 1.
10. according to claim 1 or 4 for improving the composition of human body enteral environment, it is characterised in that: described is blunt
The weight ratio of top spirulina and DHA algal oil is 1: 2-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811024291.2A CN109315769A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for improving the composition and preparation method thereof of human body enteral environment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811024291.2A CN109315769A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for improving the composition and preparation method thereof of human body enteral environment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109315769A true CN109315769A (en) | 2019-02-12 |
Family
ID=65264399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811024291.2A Pending CN109315769A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for improving the composition and preparation method thereof of human body enteral environment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109315769A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604297A (en) * | 2019-10-12 | 2019-12-24 | 襄阳市世诠生物科技有限公司 | Special medical food for old people and preparation method thereof |
| CN112210461A (en) * | 2019-07-12 | 2021-01-12 | 陆良佰佳益康生物科技有限公司 | Probiotic for regulating metabolism of intestinal fatty acid and total bile acid and detection method |
| CN113265361A (en) * | 2021-06-24 | 2021-08-17 | 微康益生菌(苏州)股份有限公司 | Compound probiotic preparation capable of relieving non-alcoholic fatty liver, preparation method and application thereof |
| EP3967318A1 (en) * | 2020-09-14 | 2022-03-16 | Bionou Research, S.L. | Probiotic compositions for the treatment of acne |
| RU2782196C1 (en) * | 2021-08-09 | 2022-10-24 | Общество с ограниченной ответственностью "АВАН-БИО" | Synbiotic composition for suppressing microbial pathogens of intestinal infections and method for production thereof |
| WO2024030943A1 (en) * | 2022-08-03 | 2024-02-08 | The Quaker Oats Company | Oat fermentation products, products prepared therefrom and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103462093A (en) * | 2013-07-18 | 2013-12-25 | 浙江劲膳美生物科技有限公司 | Special diet for people in need of toxin expelling and beauty fostering |
| CN103652855A (en) * | 2013-11-06 | 2014-03-26 | 胡安然 | Special diet for relaxing bowel |
| CN107212415A (en) * | 2017-05-18 | 2017-09-29 | 江西长通实业有限公司 | A kind of 5-linked probiotics nutrient powder and preparation method thereof |
-
2018
- 2018-09-04 CN CN201811024291.2A patent/CN109315769A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103462093A (en) * | 2013-07-18 | 2013-12-25 | 浙江劲膳美生物科技有限公司 | Special diet for people in need of toxin expelling and beauty fostering |
| CN103652855A (en) * | 2013-11-06 | 2014-03-26 | 胡安然 | Special diet for relaxing bowel |
| CN107212415A (en) * | 2017-05-18 | 2017-09-29 | 江西长通实业有限公司 | A kind of 5-linked probiotics nutrient powder and preparation method thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112210461A (en) * | 2019-07-12 | 2021-01-12 | 陆良佰佳益康生物科技有限公司 | Probiotic for regulating metabolism of intestinal fatty acid and total bile acid and detection method |
| CN110604297A (en) * | 2019-10-12 | 2019-12-24 | 襄阳市世诠生物科技有限公司 | Special medical food for old people and preparation method thereof |
| EP3967318A1 (en) * | 2020-09-14 | 2022-03-16 | Bionou Research, S.L. | Probiotic compositions for the treatment of acne |
| WO2022053711A1 (en) * | 2020-09-14 | 2022-03-17 | Bionou Research S.L. | Probiotic compositions for the treatment of acne |
| CN113265361A (en) * | 2021-06-24 | 2021-08-17 | 微康益生菌(苏州)股份有限公司 | Compound probiotic preparation capable of relieving non-alcoholic fatty liver, preparation method and application thereof |
| CN113265361B (en) * | 2021-06-24 | 2023-04-21 | 微康益生菌(苏州)股份有限公司 | Composite probiotic preparation capable of relieving non-alcoholic fatty liver, preparation method and application thereof |
| RU2782196C1 (en) * | 2021-08-09 | 2022-10-24 | Общество с ограниченной ответственностью "АВАН-БИО" | Synbiotic composition for suppressing microbial pathogens of intestinal infections and method for production thereof |
| RU2782196C9 (en) * | 2021-08-09 | 2023-03-14 | Общество с ограниченной ответственностью "АВАН-БИО" | Synbiotic composition for suppressing microbial pathogens of intestinal infections and method for production thereof |
| WO2024030943A1 (en) * | 2022-08-03 | 2024-02-08 | The Quaker Oats Company | Oat fermentation products, products prepared therefrom and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN109430666A (en) | A kind of Freeze-dry Powder of Probioctics solid beverage | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN104642870B (en) | A kind of prebiotic compositions | |
| CN1099289C (en) | Medicinal prepn. contg. beneficial bacteria named 'Junyikang' and method for preparing same | |
| CN109123295A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| CN104770816A (en) | Watermelon juice probiotic fermented beverage and preparation method thereof | |
| CN102665737A (en) | Bifidobacterium longum ATCC BAA-999 (BL999) and weight control | |
| CN101560523B (en) | Nutrient composition based on mixed fermented culture of five probiotics | |
| CN108740251A (en) | A kind of probiotic gel candy and preparation method thereof improving constipation | |
| CN111227261A (en) | Prebiotic composition and application thereof | |
| CN108850397A (en) | A kind of probiotic gel candy and preparation method thereof of only diarrhea | |
| JP2018153182A (en) | Lactobacillus plantarum tci378, and use thereof in reducing fat and improving gastrointestinal function | |
| CN110447799A (en) | A kind of complex solid plant beverage and preparation method thereof for improving intestinal flora | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| CN102742653B (en) | Brain-strengthening and nerve soothing probiotic goat milk tablet and preparation method of brain-strengthening and nerve soothing probiotic goat milk tablet | |
| KR20040027180A (en) | Lactic Acid Bacteria-Fermenting Dairy Products Used for Preventing and Treating Obesity or Diabetes Mellitus and Manufacturing Method thereof | |
| JP2009084215A (en) | Inflammatory bowel disease prophylactic or therapeutic agent | |
| CN105802876B (en) | A kind of composite probiotics ferment clover tender shoots powder preparation and its preparation method and application | |
| TWI744028B (en) | Prebiotic composition for promoting growth of clostridium butyricum and uses thereof | |
| JP2005013211A (en) | Lactobacillus-containing food composition | |
| CN108938789A (en) | A kind of more bacterium combination formulations of the adjusting intestinal microecology containing xylo-oligosaccharide | |
| KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
| CN101297820A (en) | Streptococcus faecium function signal molecule formulation and product thereof for reducing fat and slimming | |
| CN102754695A (en) | Burdock probiotics goat milk slices and method for preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |